Author: natashamason

publication

Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition.

natashamason

Most street cannabis contains large quantities of THC, the chemical in cannabis that gets people ‘high’, but there is increasing use of medicinal products that also contain CBD, a non-intoxicating cannabinoid with promising therapeutically potential. It has often been proposed that administering CBD may reduce some of the impairment caused by THC. To test this,… Continue reading Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition.

cognition enhancement, publication

Acute treatment with the PDE4 inhibitor roflumilast improves verbal word memory in healthy old individuals: a double-blind placebo-controlled study

natashamason

After many years of animal research, in which we found that inhibition of the enzyme phosphodiesterase type 4 (PDE4) improved memory in animals, we now find first evidence that this mechanism also works in humans. In this study, we tested how many words older participants (aged between 60 and 85 years old) could remember from… Continue reading Acute treatment with the PDE4 inhibitor roflumilast improves verbal word memory in healthy old individuals: a double-blind placebo-controlled study

News articles

Even Low Doses of Synthetic Cannabinoids Can Impair Cognitive Performance

natashamason

New Rochelle, NY, March 19, 2019—A new study shows that inhaled doses of as little as 2 mg of the synthetic cannabinoid JWH-018 can significantly impair critical thinking and memory, slow reaction times, and increase confusion and dissociation. The results of this placebo controlled, cross-over study are published in Cannabis and Cannabinoid Research, a peer-reviewed… Continue reading Even Low Doses of Synthetic Cannabinoids Can Impair Cognitive Performance